Skip to content
    Euclidean Capital logo

    Euclidean Capital

    New York, New York, United StatesFounded 2009
    euclidcap.comLinkedIn
    Biotech & Life SciencesAIFintechData & Analytics

    Euclidean Capital is the single-family office of the late James Simons, founder of Renaissance Technologies, based in New York City. Founded in 2009, it manages the Simons family's personal wealth with diversified investments across public and private markets, including venture capital, private equity, and life sciences.

    33% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deal in the last 12 months vs 3 prior). Their most common stage is series-b (45% of deals). Average disclosed round size is $70.0M (across 58 rounds with reported amounts).

    Find people at Euclidean Capital on Goldilocks AI

    Portfolio

    46

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    1

    Team

    GA

    Gaurav Ahluwalia

    Managing Director, Investments

    TL

    Thomas Lenehan

    Managing Director

    MM

    Monika Michalczewska

    Vice President

    CM

    Colin Mackintosh

    Investment Associate

    MM

    Monique Miller

    Head of Investment Strategy

    AC

    Ashvin Chhabra

    President

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    64 investments
    CompanyRoundAmountDate
    Savvy Wealth logoSavvy WealthSeries C$100MJan 2026
    Savvy logoSavvySeries C$100MJan 2026
    Ripple logoRippleSeries A$17MDec 2025
    Leal Therapeutics logoLeal TherapeuticsSeries A$30MAug 2025
    Neurona Therapeutics logoNeurona TherapeuticsUnknown$102MApr 2025
    Zeitview logoZeitviewUnknown$60MJan 2025
    Neurona logoNeuronaSeries A$102MJan 2025
    Leal Therapeutics logoLeal TherapeuticsSeries B$45MOct 2024
    GGrayMatterSeries B$45MJun 2024
    FundGuard logoFundGuardSeries C—Mar 2024
    SSion PowerSeries A$75MJan 2024
    Nura Bio logoNura BioSeries A—Jan 2024
    KKenai TherapeuticsSeries A$82MJan 2024
    Redesign logoRedesignUnknown$175MJan 2024
    GrayMatter Robotics logoGrayMatter RoboticsSeries B$45MJan 2024
    Leal Therapeutics logoLeal TherapeuticsSeed$45MJan 2024
    Spiral logoSpiralSeries A$28MJan 2023
    Spiral logoSpiralSeries A$28MJan 2023
    Actio Biosciences logoActio BiosciencesSeries A$55MJan 2023
    AArsenal BiosciencesSeries B$220MSep 2022
    April Tax logoApril TaxSeries A$30MJun 2022
    Possible Finance logoPossible FinanceSeries B$20MMay 2022
    AArsenal BioSeries B$220MJan 2022
    CCasma TherapeuticsSeries C$46MJan 2022
    Duality Technologies logoDuality TechnologiesSeries B$30MOct 2021
    Page 1 of 3

    Top Co-Investors

    The Column Group18 shared
    Team810 shared
    Nextech Invest Ltd.8 shared
    Samsara BioCapital8 shared
    Casdin Capital6 shared
    Alexandria Venture Investments6 shared
    Hearst Ventures5 shared
    OrbiMed5 shared
    Intel Capital4 shared
    LG Technology Ventures4 shared
    Nyca Partners4 shared
    Deerfield4 shared
    Bristol Myers Squibb4 shared
    Osage University Partners4 shared
    Canvas Prime3 shared
    Andreessen Horowitz3 shared
    Chugai Venture Fund3 shared
    Newpath Partners3 shared
    GG13 shared
    UC Investments3 shared

    Last updated: 7 October 2026